Overall trial status: Authorised, recruiting
Trial title: A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Medical conditions: Moderate to Severe Plaque Psoriasis
Status in each country: Italy:Not authorised, Hungary:Ongoing, recruitment ended, Poland:Ongoing, recruitment ended, Germany:Ongoing, recruitment ended, France:Not authorised, Spain:Ongoing, recruitment ended
Trial phase: Therapeutic confirmatory (Phase III)
Therapeutic Areas: Diseases [C] - Immune System Diseases [C20]
Primary end point: IGA score of 0 or 1 and a ≥2-grade improvement from baseline at Week 16., PASI 90 at Week 16.
Secondary end point: N/A
Age of participants: 18-64 years, 65+ years
Gender of participants: Female, Male
Trial region: In both EEA and non-EEA
Planned number of participants: 320
Sponsor: Janssen - Cilag International
Sponsor type: Pharmaceutical company
Trial product: JNJ-77242113, DEUCRAVACITINIB, Film-Coated Tablet without JNJ-77242113, Film-Coated Tablet without Deucravacitinib
Results posted: No
Overall decision date: 17/01/2024
Countries decision date: FR: 22/01/2024, IT: 22/01/2024, DE: 28/05/2024, HU: 22/01/2024, PL: 07/02/2024, ES: 29/05/2024
Last updated date: 16/07/2026
There are no reviews to display.